Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2017-09-11 Investor Presentation
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Sydney Investor Presentation 17 pages 2.9MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by the CEO of Phylogica Limited, dated September 2017. It includes company background, business strategy, product pipeline, financial details, management team, partnerships, and future plans. The content is structured as a presentation with slides, focusing on business updates, technology, and investment highlights rather than formal financial statements or regulatory disclosures. There is no indication of it being an official annual or quarterly report, audit report, earnings release, or regulatory filing. The document is clearly a presentation aimed at investors or stakeholders to provide an update on the company's business and strategy. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (11,693 characters) supports it being a full presentation rather than a brief announcement or notice.
2017-09-11 English
New Delivery Vehicles Show Improved Performance Inside Cells 4 pages 435.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Phylogica Limited dated September 5, 2017. It provides an update on the company's drug delivery platform technology, specifically new delivery vehicles showing improved performance inside cells. The content focuses on scientific progress, experimental results, and future plans for further evaluation. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a corporate update on technology development rather than a financial report, regulatory filing, or meeting material. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. The best fitting category is a general regulatory announcement or corporate update, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2017-09-04 English
Investor Presentation 23 pages 14.2MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by the CEO and CSO of Phylogica Limited, dated August 2017. It contains extensive information about the company's business model, technology platform, management team, financial details, product pipeline, commercial strategy, and partnerships. The content is structured as a presentation with slides, including charts, figures, and bullet points, aimed at providing an update on the company's operations and investment highlights. There is no indication that this is an official regulatory filing such as an annual or interim report, audit report, or earnings release. It is not a transcript of a call, nor a legal or governance document. The document is clearly a presentation intended for investors or stakeholders to communicate the company's strategy, technology, and financial position. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2017-08-31 English
Appendix 4E - Preliminary Final Report 30 June 2017 15 pages 282.9KB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E Preliminary Final Report Year ended 30 June 2017' and contains detailed financial statements including profit and loss, financial position, cash flows, and notes to the financial statements. It includes directors' commentary, operating results, corporate updates, and detailed financial data for the full fiscal year ending 30 June 2017. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content aligns with a comprehensive annual financial report rather than a short earnings release or announcement. The presence of detailed financial statements and notes confirms it is a full Annual Report. Therefore, the document should be classified as an Annual Report (10-K equivalent). FY 2017
2017-08-30 English
Phylogica Investor Briefing - August 2017 Amended 13 pages 1.3MB
Investor Presentation Classification · 95% confidence The document is titled 'Phylogica Investor Briefing' dated August 2017 and contains detailed information about the company's business, corporate profile, research programs, collaborations, and scientific data. It is structured as a presentation with slides, charts, and explanations about the company's technology platform, drug development pipeline, and ongoing projects. There is no indication that this is a formal regulatory filing such as an annual or quarterly report, audit report, or earnings release. The document is clearly a presentation aimed at investors, providing an update on the company's strategy, scientific progress, and collaborations. It does not contain formal financial statements or regulatory disclosures. Therefore, the document best fits the category of an Investor Presentation (IP). The document length (over 14,000 characters) and detailed content support this classification with high confidence.
2017-08-20 English
Phylogica Investor Briefing - August 2017 13 pages 1.3MB
Investor Presentation Classification · 95% confidence The document is titled 'Phylogica Investor Briefing' dated August 2017 and contains detailed presentation slides about the company's business, technology platform, programs, collaborations, and corporate profile. It includes forward-looking statements, disclaimers, and detailed scientific and business updates. The content is structured as a presentation aimed at investors, focusing on financials, strategy, and market position rather than a formal regulatory filing or financial report. There are no financial statements or audit information, nor is it a transcript of a call or a voting result announcement. The document is a detailed investor presentation, not an annual or interim report, nor a regulatory announcement. Therefore, the most appropriate classification is 'Investor Presentation' (IP). The document length (over 14,000 characters) supports it being a full presentation rather than a brief announcement.
2017-08-17 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.